- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02913014
Comparison of Recurrence of Atrial Fibrillation Post Cryoballon Ablation During the 90-day Blanking Period-with and Without Anti-arrhythmic Drug Therapy
March 15, 2021 updated by: Prisma Health-Midlands
Monitoring Safety and Recurrence of Paroxysmal Atrial Fibrillation After 1st Cryo-balloon Ablation With and Without Antiarrhythmic Drug Therapy During the 90-day Blanking Period - Examined With Adverse Event Monitoring and Cardiovascular Implantable Electronic Devices (CIEDs)
This study is being done to find out if patients taking Anti Arrhythmia Drugs (AADs) after cryoballoon ablation for atrial fibrillation, compared to patients who do not take Anti- Arrhythmic Drugs after an ablation affect Atrial Fibrillation from coming back.
The study will also look at the side effects of the AADs.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Pulmonary vein isolation (PVI) is a cornerstone ablation strategy used in the management of paroxysmal atrial fibrillation (PAF), and it is a class IA indication for anti-arrhythmic drug (AAD) refractory symptomatic PAF.
However, the consensus statements are vague about the utility of AAD management during the 90-day blanking window post-PVI.
Moreover, there is no specific guidance to cryoballoon users on the usage of AADs during the 90-day blanking period that exists anywhere in the published literature.
Simply, these studies have not been conducted with the cryoballoon procedure.
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
South Carolina
-
Columbia, South Carolina, United States, 29203
- Palmetto Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Drug refractory and recurrent Paroxysmal Atrial Fibrillation
- The subject meets medical criteria for cryoballoon ablation to treat Paroxysmal AF
- Age 18 to 80 years
- The subject has a Cardiovascular Implantable Electronic Device (CIED) that captures AF episodes, such as an implantable loop recorder, pacemaker, or implantable cardioverter defibrillator (ICD) with a properly functioning atrial lead.
Exclusion Criteria:
- Use of any Anti- Arrhythmic Drugs for ventricular arrhythmias
- Ejection Fraction (EF)<45%
- Prior A. Fib. ablation
- Pregnant women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm 1- No AAD post Ablation
Subjects will not resume their Anti Arrhythmic Drugs after cryoballoon-ablation for paroxysmal atrial fibrillation.
|
Subjects will not resume their pre-ablation anti-arrhythmic medications during the 90 following cryo ablation for Atrial Fibrillation
Other Names:
|
No Intervention: Arm 2-Resume AAD post Ablation
Subjects will resume their pre-ablation Anti Arrhythmic Drugs after cryoballoon-ablation for paroxysmal atrial fibrillation, during the 90 day blanking period following the ablation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare recurrence, recurrence rate, burden of atrial fibrillation post ablation between the two groups.
Time Frame: 12 months
|
Rhythm status through implantable loop recorder (or pacemaker with functioning atrial lead) at 3 month, 6 month, 12 month compared between two treatment groups, including: A) AF burden (Average amount of time in AF per day) B) AF recurrence rate (Frequency of AF, occurrences per day) C) Time to AF recurrence |
12 months
|
Symptom Assessments
Time Frame: 12 months
|
Symptom assessments by clinical follow up and phone calls, including symptom severity score using the Severity of Atrial Fibrillation Scale between the two groups.
|
12 months
|
Adverse Events Assessments
Time Frame: 12 months
|
Ongoing assessment of adverse events in both arms of the study, including AADs side effects in 90-day blanking period.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The cost of AADs during the 90-day blanking period.
Time Frame: 12 months
|
The cost of AADs during the 90-day blanking period.
|
12 months
|
Assess the rate of hospitalizations, emergency room visits, and unscheduled cardiology visits for the treatment of AF between the two groups
Time Frame: 12 months
|
A) Event during the 90-day blanking period will be assessed for AAD related and unrelated adverse events that caused the cardiac related visit
|
12 months
|
The differential usage of anticoagulation therapy between two arms.
Time Frame: 12 months
|
The differential usage of anticoagulation therapy between two arms.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Sultan M Siddique, MD, Prisma Health-Midlands
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 28, 2017
Primary Completion (Actual)
December 31, 2020
Study Completion (Actual)
December 31, 2020
Study Registration Dates
First Submitted
August 31, 2016
First Submitted That Met QC Criteria
September 22, 2016
First Posted (Estimate)
September 23, 2016
Study Record Updates
Last Update Posted (Actual)
March 17, 2021
Last Update Submitted That Met QC Criteria
March 15, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00055684
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
Beijing Anzhen HospitalJohnson & Johnson; Heart Health Research CenterNot yet recruitingParoxysmal Atrial Fibrillation | Persistent Atrial Fibrillation
-
Maastricht UniversityRadboud University Medical Center; Maastricht University Medical CenterRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Atrial Fibrillation ParoxysmalNetherlands
Clinical Trials on No AAD post Ablation.
-
Boston Scientific CorporationCompleted
-
CardioFocusTerminatedAtrial FibrillationUnited States
-
Cedars-Sinai Medical CenterRecruitingStress Urinary IncontinenceUnited States
-
Denver Health and Hospital AuthorityCompletedTibia FractureUnited States
-
Seoul National University HospitalSamsung Medical Center; Chosun University HospitalTerminatedRadiofrequency Ablation | Microwave AblationKorea, Republic of
-
Steba Biotech S.A.ICON plc; International Drug Development InstituteCompletedCancer of the ProstateNetherlands, Spain, France, Germany, United Kingdom, Finland, Italy, Sweden
-
Rush University Medical CenterMedical University of South Carolina; University of Michigan; The Cleveland Clinic and other collaboratorsNot yet recruitingVentricular Tachycardia | Ischemic CardiomyopathyUnited States
-
Rambam Health Care CampusCompletedVocal Cord Dysfunction | Vocal Fold PolypIsrael
-
NYU Langone HealthWithdrawnBreast CancerUnited States
-
CSA Medical, Inc.TerminatedBarrett's Esophagus | Low Grade Dysplasia | High Grade DysplasiaUnited States